A case report of plasma exchange, steroids, mycophenolate mofetil and cyclophosphamide in acquired factor VIII inhibitors

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 5, 2008, Pages 406-408

  Rech, Jürgen ^a   Hueber, Axel J ^a   Leipe, Jan ^b   Manger, Bernhard ^a   Schett, Georg ^a   Kallert, Stefan ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acquired factor VIII inhibitor; Mycophenolate mofetil; Plasma exchange

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FRESH FROZEN PLASMA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CASE REPORT; DRUG MEGADOSE; HEMOPHILIA; HUMAN; MALE; PECTORALIS MAJOR MUSCLE; PHYSICAL EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; ERYTHROCYTE TRANSFUSION; FACTOR VIII; FOLLOW-UP STUDIES; HEMOPHILIA A; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MYCOPHENOLIC ACID; PLASMA EXCHANGE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 53749083542     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00618.x     Document Type: Article

References (14)

1. Delgado J, Jiminez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors Br J Haematol 2003 121 : 21 35.
2. Macik BG, Hohneker J, Roberts HR, Griffin AM. Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor. Am J Hematol 1989 32 : 232 4.
3. Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993 70 : 753 7.
4. Pirner K, Roesler W, Kalden JR, Manger B. Long-term remission after i.v. immunoglobulin therapy in acquired antihemophilic factor hemophilia with systemic lupus erythematosus. Z Rheumatol 1990 49 : 378 81.
5. Bona RD, Pasquale DN, Kalish RI, Witter BA. Porcine factor VIII and plasmapheresis in the management of hemophiliac patients with inhibitors. Am J Hematol 1986 21 : 201 17.
6. Knöbl P, Derfler K. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 1999 77 (Suppl. 1 57 64.
7. Zeitler H, Ulrich-Merzenich G, Hess L et al. Treatment of acquired hemophilia by the Bonn-Malmö Protocol: documentation of an in vivo immunomodulating concept. Blood 2005 105 : 2287 2293.
8. Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002 100 : 3426 8.
9. Sallah S, Wan JY. Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. Blood 2003 101 : 943 5.
10. Francesconi M, Korninger C, Thaler E, Niessner H, Höcker P, Lechner K. Plasmapheresis: its value in the management of patients with antibodies to factor VIII. Haemostasis 1982 11 : 79 85.
11. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004 127 : 379 91.
12. Levine E. Transitional cell carcinoma of the renal pelvis associated with cyclophosphamide therapy. AJR Am J Roentgenol 1992 159 : 1027 8.
13. Bowles KM, Callaghan CJ, Taylor AL et al. Inhibitors in congenital coagulation disorders. Br J Anaesth 2006 97 : 476 81. Epub 2006 August 16.
14. Fischer K-G, Deschler B, Lübbert M. Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmapheresis. Blood 2003 101 : 3753 4.